Sanofi Drug Patent Portfolio
Sanofi owns 22 orange book drugs protected by 119 US patents with Avalide having the least patent protection, holding only 2 patents. And Soliqua 100/33 with maximum patent protection, holding 26 patents. Given below is the list of Sanofi's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9950039 | Insulin glargine/lixisenatide fixed ratio formulation | 10 Dec, 2035 | Active |
| US10369291 | Mechanism for a drug delivery device | 16 Sep, 2035 | Active |
| US9186346 | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients | 04 Aug, 2034 | Active |
| US10201663 | Assembly for a drug delivery device | 10 Mar, 2034 | Active |
| US9186346 | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients | 04 Feb, 2034 | Active |
| US9717852 | Cartridge holder and pen-type injector | 08 Apr, 2033 | Active |
| US9408893 | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients | 27 Aug, 2032 | Active |
| US9821032 | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin | 09 May, 2032 | Active |
| US9072836 | Drive mechanism for a drug delivery device and drug delivery device | 15 Mar, 2032 | Active |
| US9440029 | Drive mechanism for a drug delivery device and drug delivery device | 30 Jan, 2032 | Active |
| US9511193 | Assembly and indicator for a drug delivery device | 19 Jan, 2032 | Active |
| US9084853 | Drive mechanism for a drug delivery device and drug delivery device | 05 Oct, 2031 | Active |
| US8602215 | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation | 30 Jun, 2031 | Active |
| US8882721 | Drive assembly suitable for use in a drug delivery device and drug delivery device | 28 Jun, 2031 | Active |
| US9345750 | Long-acting formulations of insulin | 18 May, 2031 | Active |
| US8927592 | Antitumoral use of cabazitaxel | 27 Apr, 2031 | Active |
| US8802735 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | 14 Mar, 2031 | Active |
| US8475414 | Medication delivery device and method for operating a medication delivery device | 28 Dec, 2030 | Active |
| US9308329 | Medication delivery device and method for operating a medication delivery device | 28 Dec, 2030 | Active |
| US10028910 | Pharmaceutical composition comprising a GLP-1-agonist and methionine | 11 Nov, 2030 | Active |
| US9707176 | Pharmaceutical composition comprising a GLP-1 agonist and methionine | 11 Nov, 2030 | Active |
| US10029011 | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine | 11 Nov, 2030 | Active |
| US10583110 | Antitumoral use of cabazitaxel | 27 Oct, 2030 | Active |
| US10716777 | Antitumoral use of cabazitaxel | 27 Oct, 2030 | Active |
| US12453712 | 27 Oct, 2030 | Active | |
| US8927592 | Antitumoral use of cabazitaxel | 27 Oct, 2030 | Active |
| US8802735 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | 14 Sep, 2030 | Active |
| US9981013 | Use of AVE0010 for the treatment of diabetes mellitus type 2 | 30 Aug, 2030 | Active |
| US8915888 | Dosing and drive mechanism for drug delivery device | 08 Jun, 2030 | Active |
| US10117909 | Combination of an insulin and a GLP-1 agonist | 09 Oct, 2029 | Active |
| US9526764 | Combination of an insulin and a GLP-1-agonist | 09 Oct, 2029 | Active |
| US9855388 | Dosing and drive mechanism for drug delivery device | 24 Apr, 2029 | Active |
| US8410167 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality | 16 Apr, 2029 | Active |
| US9107900 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality | 16 Apr, 2029 | Active |
| US7918833 | Pen-type injector | 23 Mar, 2028 | Active |
| US7918833 | Pen-type injector | 23 Sep, 2027 | Active |
| US6794410 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis | 12 Mar, 2027 | Active |
| US6794410 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis | 12 Sep, 2026 | Active |
| US7241907 | Acetone solvate of dimethoxy docetaxel and its process of preparation | 10 Jun, 2026 | Active |
| US7241907 | Acetone solvate of dimethoxy docetaxel and its process of preparation | 10 Dec, 2025 | Expired |
| US7985418 | Aliphatic amine polymer salts for tableting | 27 Oct, 2025 | Expired |
| US8679069 | Pen-type injector | 12 Apr, 2025 | Expired |
| US8512297 | Pen-type injector | 15 Sep, 2024 | Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices | 28 Aug, 2024 | Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices | 19 Aug, 2024 | Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices | 17 Aug, 2024 | Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices | 16 Aug, 2024 | Expired |
| US8992486 | Pen-type injector | 05 Jun, 2024 | Expired |
| US9011391 | Pen-type injector | 26 Mar, 2024 | Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices | 03 Mar, 2024 | Expired |
| US8603044 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9233211 | Relating to a pen-type injector | 02 Mar, 2024 | Expired |
| US9408979 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9526844 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
| US9775954 | Pen-type injector | 02 Mar, 2024 | Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices | 02 Mar, 2024 | Expired |
| US7476652 | Acidic insulin preparations having improved stability | 23 Jan, 2024 | Expired |
| US7713930 | Acidic insulin preparations having improved stability | 13 Dec, 2023 | Expired |
| US7148211 | Formulation for lipophilic agents | 14 Sep, 2023 | Expired |
| US7476652 | Acidic insulin preparations having improved stability | 23 Jul, 2023 | Expired |
| US7713930 | Acidic insulin preparations having improved stability | 13 Jun, 2023 | Expired |
| US6960561 | Zinc-free and low-zinc insulin preparations having improved stability | 25 Jan, 2023 | Expired |
| US7148207 | Oral fludara of high-purity formulation with quick release of active ingredient | 20 Dec, 2022 | Expired |
| US7452860 | Zinc-free and low-zinc insulin preparations having improved stability | 22 Mar, 2022 | Expired |
| US7696162 | Zinc-free and low-zinc insulin preparations having improved stability | 22 Mar, 2022 | Expired |
| US5847170 | Taxoids, their preparation and pharmaceutical compositions containing them | 26 Sep, 2021 | Expired |
| US6903083 | Stabilized hydroxyvitamin D | 18 Jul, 2021 | Expired |
| USRE45313 | Exendin variant peptides | 12 Jul, 2020 | Expired |
| US6429210 | Polymorphic clopidogrel hydrogenesulphate form | 10 Dec, 2019 | Expired |
| US6504030 | Polymorphic form of clopidogrel hydrogen sulphate | 10 Dec, 2019 | Expired |
| US6429210 | Polymorphic clopidogrel hydrogenesulphate form | 10 Jun, 2019 | Expired |
| US6504030 | Polymorphic form of clopidogrel hydrogen sulphate | 10 Jun, 2019 | Expired |
| US7547776 | Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5% | 10 Dec, 2018 | Expired |
| US7323493 | Solid pharmaceutical composition containing benzofuran derivatives | 19 Jun, 2018 | Expired |
| US8318800 | Solid pharmaceutical compositions containing benzofuran derivatives | 19 Jun, 2018 | Expired |
| US6221633 | Insulin derivatives having a rapid onset of action | 18 Jun, 2018 | Expired |
| US5635485 | Erythromycin compounds | 01 Apr, 2018 | Expired |
| US5420319 | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same | 09 Feb, 2017 | Expired |
| US5420319 | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same | 09 Aug, 2016 | Expired |
| US5223510 | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them | 26 Jul, 2016 | Expired |
| US5976573 | Aqueous-based pharmaceutical composition | 03 Jul, 2016 | Expired |
| US6143329 | Aqueous-based pharmaceutical composition | 03 Jul, 2016 | Expired |
| US7977045 | Aqueous-based pharmaceutical composition | 03 Jul, 2016 | Expired |
| US5847170 | Taxoids, their preparation and pharmaceutical compositions containing them | 26 Mar, 2016 | Expired |
| US6331635 | Taxoids, their preparation and pharmaceutical compositions containing them | 26 Mar, 2016 | Expired |
| US6372780 | Methods of treating cell lines expressing multidrug resistance P-glycoprotein | 26 Mar, 2016 | Expired |
| US6387946 | Methods for treating pathological conditions of abnormal cell proliferation | 26 Mar, 2016 | Expired |
| US5716988 | Pharmaceutically stable preparation of oxaliplatinum | 07 Feb, 2016 | Expired |
| US5994348 | Pharmaceutical compositions containing irbesartan | 07 Dec, 2015 | Expired |
| US6342247 | Pharmaceutical compositions containing irbesartan | 07 Dec, 2015 | Expired |
| USD459798 | Pill tablet | 24 Sep, 2015 | Expired |
| US5716988 | Pharmaceutically stable preparation of oxaliplatinum | 07 Aug, 2015 | Expired |
| US5994348 | Pharmaceutical compositions containing irbesartan | 07 Jun, 2015 | Expired |
| US6342247 | Pharmaceutical compositions containing irbesartan | 07 Jun, 2015 | Expired |
| US5656722 | A21 -, B30 - modified insulin derivatives having an altered action profile | 12 Feb, 2015 | Expired |
| US5679709 | Medicaments to combat autoimmune diseases | 21 Oct, 2014 | Expired |
| US5667775 | Phosphate-binding polymers for oral administration | 16 Sep, 2014 | Expired |
| US5656722 | A21 -, B30 - modified insulin derivatives having an altered action profile | 12 Aug, 2014 | Expired |
| US5438072 | Taxoid-based compositions | 22 May, 2014 | Expired |
| US5602116 | Method for treating and preventing secondary hyperparathyroidism | 11 Feb, 2014 | Expired |
| US5438072 | Taxoid-based compositions | 22 Nov, 2013 | Expired |
| US5338874 | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity | 07 Oct, 2013 | Expired |
| US5496545 | Phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
| US6509013 | Method of making phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
| US6858203 | Method of making phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
| US7014846 | Phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
| US7459151 | Phosphate-binding polymers for oral administration | 11 Aug, 2013 | Expired |
| US5290961 | Platinum compound and process of preparing same | 12 Jul, 2013 | Expired |
| US5338874 | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity | 07 Apr, 2013 | Expired |
| US5290961 | Platinum compound and process of preparing same | 12 Jan, 2013 | Expired |
| US5698582 | Compositions containing taxane derivatives | 03 Jan, 2013 | Expired |
| US5714512 | Compositions containing taxane derivatives | 03 Jan, 2013 | Expired |
| US5750561 | Compositions containing taxane derivatives | 03 Jan, 2013 | Expired |
| US5459163 | Medicament to combat autoimmune diseases | 17 Oct, 2012 | Expired |
| US5698582 | Compositions containing taxane derivatives | 03 Jul, 2012 | Expired |
| US5714512 | Compositions containing taxane derivatives | 03 Jul, 2012 | Expired |
| US5750561 | Compositions containing taxane derivatives | 03 Jul, 2012 | Expired |
Latest Legal Activities on Sanofi's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sanofi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9533105 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9533105 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9533105 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jun, 2024 | US9526764 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9511193 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Feb, 2024 | US9440029 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2024 | US9408979 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2024 | US9408893 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2024 | US9408979 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jan, 2024 | US9408979 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jan, 2024 | US10716777 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Nov, 2023 | US9345750 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Nov, 2023 | US9345750 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Sep, 2023 | US9308329 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Aug, 2023 | US10583110 |
Sanofi's Drug Patent Litigations
Sanofi's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 17, 2016, against patent number US5847170. The petitioner Mylan Laboratories Limited et al., challenged the validity of this patent, with Aventis Pharma S.A. et al. as the respondent. Click below to track the latest information on how companies are challenging Sanofi's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8679069 | May, 2019 |
FWD Entered
(11 Aug, 2020)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8679069 | May, 2019 |
Final Written Decision
(11 Aug, 2020)
| Sanofi-Aventis Deutschland et al. | Pfizer Inc. |
| US9604008 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8992486 | October, 2018 |
Final Written Decision
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
| US8992486 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US9526844 | September, 2018 |
Final Written Decision
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
| US8992486 | September, 2018 |
Final Written Decision
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
| US9604008 | September, 2018 |
Final Written Decision
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
| US8992486 | October, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8603044 | September, 2018 |
Final Written Decision
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
| US9526844 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US9526844 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc |
| US9526844 | September, 2018 |
Final Written Decision
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc et al. |
| US8603044 | September, 2018 |
FWD Entered
(29 May, 2020)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US8679069 | September, 2018 |
FWD Entered
(02 Apr, 2020)
| Sanofi-Aventis Deutshland GmbH | Mylan Pharmaceuticals Inc. |
| US8679069 | September, 2018 |
Final Written Decision
(02 Apr, 2020)
| Sanofi-Aventis Deutshland GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
| US9526844 | May, 2019 |
Terminated-Other
(20 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9526844 | May, 2019 |
Terminated-Other
(19 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US9604008 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8603044 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US8992486 | May, 2019 |
Terminated-Other
(15 Aug, 2019)
| Sanofi-Aventis Deutschland | Pfizer Inc. |
| US5847170 | October, 2018 |
Institution Denied
(06 May, 2019)
| Aventis Pharma S.A. et al. | Neptune Generics, LLC et al. |
| US5847170 | October, 2018 |
Terminated-Denied
(06 May, 2019)
| Aventis Pharma S.A. | Neptune Generics, LLC |
| US9526844 | September, 2018 |
Terminated-Denied
(03 Apr, 2019)
| Sanofi-Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc. |
| US9526844 | September, 2018 |
Institution Denied
(03 Apr, 2019)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc. et al. |
| US8992486 | September, 2018 |
Terminated
(19 Dec, 2018)
| Sanofi-Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc et al. |
| US7713930 | June, 2017 |
FWD Entered
(12 Dec, 2018)
| Sanofi Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc., |
| US7713930 | June, 2017 |
Final Written Decision
(12 Dec, 2018)
| Sanofi Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc., et al. |
| US7476652 | June, 2017 |
Final Written Decision
(12 Dec, 2018)
| Sanofi Aventis Deutschland GmbH et al. | Mylan Pharmaceuticals Inc., et al. |
| US7476652 | June, 2017 |
FWD Entered
(12 Dec, 2018)
| Sanofi Aventis Deutschland GmbH | Mylan Pharmaceuticals Inc., |
| US8927592 | March, 2016 |
Final Written Decision
(21 Sep, 2017)
| AVENTIS PHARMA S.A. et al. | Mylan Laboratories Limited et al. |
| US5847170 | February, 2016 |
Terminated-Denied
(23 Aug, 2016)
| Aventis Pharma S.A. | Mylan Laboratories Limited |
| US5847170 | February, 2016 |
Institution Denied
(23 Aug, 2016)
| Aventis Pharma S.A. et al. | Mylan Laboratories Limited et al. |
Sanofi Drug Patents' Oppositions Filed in EPO
Sanofi drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 14, 2013, by Stada Arzneimittel Ag. This opposition was filed on patent number EP04787385A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP10782039A | Dec, 2021 | Maiwald Patent- und Rechtsanwaltsgesellschaft mbH | Granted and Under Opposition |
| EP10782039A | Dec, 2021 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP10782039A | Dec, 2021 | Vossius & Partner Patentanwälte Rechtsanwälte mbB | Granted and Under Opposition |
| EP10782039A | Jun, 2021 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Dr. Reddy's Laboratories Ltd./ Betapharm Arzneimittel GmbH | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Fresenius Kabi Deutschland GmbH | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | medac Gesellschaft für klinische Spezialpräparate mbH | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Zentiva k.s. | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | EVER Valinject GmbH | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Glenmark Pharmaceuticals Europe Ltd | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP10782039A | Mar, 2021 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP10752585A | Jan, 2018 | Pentafarma Sociedade Técnico-Medicinal S.A. | Revoked |
| EP10752585A | Dec, 2017 | Wuesthoff & Wuesthoff Patentanwälte PartG mbB | Revoked |
| EP10752585A | Dec, 2017 | Cooke, Richard | Revoked |
| EP04787385A | Oct, 2013 | STADA Arzneimittel AG | Opposition rejected |
Sanofi's Family Patents
Sanofi drugs have patent protection in a total of 56 countries. It's US patent count contributes only to 18.3% of its total global patent coverage. 18 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Sanofi Drug List
Given below is the complete list of Sanofi's drugs and the patents protecting them.
1. Adlyxin
Adlyxin is protected by 16 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10201663 | Assembly for a drug delivery device |
10 Mar, 2034
(8 years from now)
| Active |
| US9408893 | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
27 Aug, 2032
(6 years from now)
| Active |
| US9821032 | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
09 May, 2032
(6 years from now)
| Active |
| US9072836 | Drive mechanism for a drug delivery device and drug delivery device |
15 Mar, 2032
(6 years from now)
| Active |
| US9440029 | Drive mechanism for a drug delivery device and drug delivery device |
30 Jan, 2032
(6 years from now)
| Active |
| US9511193 | Assembly and indicator for a drug delivery device |
19 Jan, 2032
(5 years from now)
| Active |
| US9084853 | Drive mechanism for a drug delivery device and drug delivery device |
05 Oct, 2031
(5 years from now)
| Active |
| US8882721 | Drive assembly suitable for use in a drug delivery device and drug delivery device |
28 Jun, 2031
(5 years from now)
| Active |
| US8475414 | Medication delivery device and method for operating a medication delivery device |
28 Dec, 2030
(4 years from now)
| Active |
| US9308329 | Medication delivery device and method for operating a medication delivery device |
28 Dec, 2030
(4 years from now)
| Active |
| US10028910 | Pharmaceutical composition comprising a GLP-1-agonist and methionine |
11 Nov, 2030
(4 years from now)
| Active |
| US9707176 | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
11 Nov, 2030
(4 years from now)
| Active |
| US9981013 | Use of AVE0010 for the treatment of diabetes mellitus type 2 |
30 Aug, 2030
(4 years from now)
| Active |
| US8915888 | Dosing and drive mechanism for drug delivery device |
08 Jun, 2030
(4 years from now)
| Active |
| US9855388 | Dosing and drive mechanism for drug delivery device |
24 Apr, 2029
(3 years from now)
| Active |
| USRE45313 | Exendin variant peptides |
12 Jul, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Adlyxin's drug page
2. Admelog Solostar
Admelog Solostar is protected by 19 patents, out of which 17 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9717852 | Cartridge holder and pen-type injector |
08 Apr, 2033
(7 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(1 year, 7 months from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(9 months ago)
| Expired |
| US8512297 | Pen-type injector |
15 Sep, 2024
(1 year, 4 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(1 year, 4 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(1 year, 7 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(1 year, 9 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
04 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Admelog Solostar's drug page
3. Apidra
Apidra is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6960561 | Zinc-free and low-zinc insulin preparations having improved stability |
25 Jan, 2023
(2 years ago)
| Expired |
| US7452860 | Zinc-free and low-zinc insulin preparations having improved stability |
22 Mar, 2022
(3 years ago)
| Expired |
| US7696162 | Zinc-free and low-zinc insulin preparations having improved stability |
22 Mar, 2022
(3 years ago)
| Expired |
| US6221633 | Insulin derivatives having a rapid onset of action |
18 Jun, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Apidra's drug page
4. Apidra Solostar
Apidra Solostar is protected by 23 patents, out of which 21 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9717852 | Cartridge holder and pen-type injector |
08 Apr, 2033
(7 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(1 year, 7 months from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(9 months ago)
| Expired |
| US8512297 | Pen-type injector |
15 Sep, 2024
(1 year, 4 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(1 year, 4 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(1 year, 7 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(1 year, 9 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US6960561 | Zinc-free and low-zinc insulin preparations having improved stability |
25 Jan, 2023
(2 years ago)
| Expired |
| US7452860 | Zinc-free and low-zinc insulin preparations having improved stability |
22 Mar, 2022
(3 years ago)
| Expired |
| US7696162 | Zinc-free and low-zinc insulin preparations having improved stability |
22 Mar, 2022
(3 years ago)
| Expired |
| US6221633 | Insulin derivatives having a rapid onset of action |
18 Jun, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Apidra Solostar's drug page
5. Aubagio
Aubagio is protected by 8 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9186346
(Pediatric)
| Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
04 Aug, 2034
(8 years from now)
| Active |
| US9186346 | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
04 Feb, 2034
(8 years from now)
| Active |
| US8802735
(Pediatric)
| (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
14 Mar, 2031
(5 years from now)
| Active |
| US8802735 | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
14 Sep, 2030
(4 years from now)
| Active |
| US6794410
(Pediatric)
| Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
12 Mar, 2027
(1 year, 1 month from now)
| Active |
| US6794410 | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
12 Sep, 2026
(7 months from now)
| Active |
| US5679709 | Medicaments to combat autoimmune diseases |
21 Oct, 2014
(11 years ago)
| Expired |
| US5459163 | Medicament to combat autoimmune diseases |
17 Oct, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aubagio's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Avalide
Avalide is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5994348
(Pediatric)
| Pharmaceutical compositions containing irbesartan |
07 Dec, 2015
(10 years ago)
| Expired |
| US5994348 | Pharmaceutical compositions containing irbesartan |
07 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avalide's drug page
7. Avapro
Avapro is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6342247
(Pediatric)
| Pharmaceutical compositions containing irbesartan |
07 Dec, 2015
(10 years ago)
| Expired |
| US6342247 | Pharmaceutical compositions containing irbesartan |
07 Jun, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avapro's drug page
8. Eloxatin
Eloxatin is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5420319
(Pediatric)
| Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
09 Feb, 2017
(8 years ago)
| Expired |
| US5420319 | Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same |
09 Aug, 2016
(9 years ago)
| Expired |
| US5716988
(Pediatric)
| Pharmaceutically stable preparation of oxaliplatinum |
07 Feb, 2016
(9 years ago)
| Expired |
| US5716988 | Pharmaceutically stable preparation of oxaliplatinum |
07 Aug, 2015
(10 years ago)
| Expired |
| US5338874
(Pediatric)
| Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
07 Oct, 2013
(12 years ago)
| Expired |
| US5290961
(Pediatric)
| Platinum compound and process of preparing same |
12 Jul, 2013
(12 years ago)
| Expired |
| US5338874 | Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity |
07 Apr, 2013
(12 years ago)
| Expired |
| US5290961 | Platinum compound and process of preparing same |
12 Jan, 2013
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eloxatin's drug page
9. Hectorol
Hectorol is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7148211 | Formulation for lipophilic agents |
14 Sep, 2023
(2 years ago)
| Expired |
| US6903083 | Stabilized hydroxyvitamin D |
18 Jul, 2021
(4 years ago)
| Expired |
| US5602116 | Method for treating and preventing secondary hyperparathyroidism |
11 Feb, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hectorol's drug page
10. Jevtana Kit
Jevtana Kit is protected by 14 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8927592
(Pediatric)
| Antitumoral use of cabazitaxel |
27 Apr, 2031
(5 years from now)
| Active |
| US10583110 | Antitumoral use of cabazitaxel |
27 Oct, 2030
(4 years from now)
| Active |
| US10716777 | Antitumoral use of cabazitaxel |
27 Oct, 2030
(4 years from now)
| Active |
| US12453712 |
27 Oct, 2030
(4 years from now)
| Active | |
| US8927592 | Antitumoral use of cabazitaxel |
27 Oct, 2030
(4 years from now)
| Active |
| US7241907
(Pediatric)
| Acetone solvate of dimethoxy docetaxel and its process of preparation |
10 Jun, 2026
(4 months from now)
| Active |
| US7241907 | Acetone solvate of dimethoxy docetaxel and its process of preparation |
10 Dec, 2025
(a month ago)
| Expired |
| US5847170
(Pediatric)
| Taxoids, their preparation and pharmaceutical compositions containing them |
26 Sep, 2021
(4 years ago)
| Expired |
| US5847170 | Taxoids, their preparation and pharmaceutical compositions containing them |
26 Mar, 2016
(9 years ago)
| Expired |
| US6331635 | Taxoids, their preparation and pharmaceutical compositions containing them |
26 Mar, 2016
(9 years ago)
| Expired |
| US6372780 | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
26 Mar, 2016
(9 years ago)
| Expired |
| US6387946 | Methods for treating pathological conditions of abnormal cell proliferation |
26 Mar, 2016
(9 years ago)
| Expired |
| US5438072 | Taxoid-based compositions |
22 Nov, 2013
(12 years ago)
| Expired |
| US5698582 | Compositions containing taxane derivatives |
03 Jul, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jevtana Kit's drug page
11. Ketek
Ketek is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5635485 | Erythromycin compounds |
01 Apr, 2018
(7 years ago)
| Expired |
| USD459798 | Pill tablet |
24 Sep, 2015
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ketek's drug page
12. Lantus
Lantus is protected by 8 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7918833
(Pediatric)
| Pen-type injector |
23 Mar, 2028
(2 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(1 year, 7 months from now)
| Active |
| US7476652
(Pediatric)
| Acidic insulin preparations having improved stability |
23 Jan, 2024
(2 years ago)
| Expired |
| US7713930
(Pediatric)
| Acidic insulin preparations having improved stability |
13 Dec, 2023
(2 years ago)
| Expired |
| US7476652 | Acidic insulin preparations having improved stability |
23 Jul, 2023
(2 years ago)
| Expired |
| US7713930 | Acidic insulin preparations having improved stability |
13 Jun, 2023
(2 years ago)
| Expired |
| US5656722
(Pediatric)
| A21 -, B30 - modified insulin derivatives having an altered action profile |
12 Feb, 2015
(10 years ago)
| Expired |
| US5656722 | A21 -, B30 - modified insulin derivatives having an altered action profile |
12 Aug, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lantus's drug page
13. Lantus Solostar
Lantus Solostar is protected by 18 patents, out of which 17 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9717852 | Cartridge holder and pen-type injector |
08 Apr, 2033
(7 years from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(9 months ago)
| Expired |
| US8512297 | Pen-type injector |
15 Sep, 2024
(1 year, 4 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(1 year, 4 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(1 year, 7 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(1 year, 9 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lantus Solostar's drug page
14. Multaq
Multaq is protected by 6 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8602215 | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
30 Jun, 2031
(5 years from now)
| Active |
| US8410167 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
16 Apr, 2029
(3 years from now)
| Active |
| US9107900 | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
16 Apr, 2029
(3 years from now)
| Active |
| US7323493 | Solid pharmaceutical composition containing benzofuran derivatives |
19 Jun, 2018
(7 years ago)
| Expired |
| US8318800 | Solid pharmaceutical compositions containing benzofuran derivatives |
19 Jun, 2018
(7 years ago)
| Expired |
| US5223510 | Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them |
26 Jul, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Multaq's drug page
15. Nasacort Aq
Nasacort Aq is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5976573 | Aqueous-based pharmaceutical composition |
03 Jul, 2016
(9 years ago)
| Expired |
| US6143329 | Aqueous-based pharmaceutical composition |
03 Jul, 2016
(9 years ago)
| Expired |
| US7977045 | Aqueous-based pharmaceutical composition |
03 Jul, 2016
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nasacort Aq's drug page
16. Oforta
Oforta is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7148207 | Oral fludara of high-purity formulation with quick release of active ingredient |
20 Dec, 2022
(3 years ago)
| Expired |
| US7547776 | Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5% |
10 Dec, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oforta's drug page
17. Plavix
Plavix is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6429210
(Pediatric)
| Polymorphic clopidogrel hydrogenesulphate form |
10 Dec, 2019
(6 years ago)
| Expired |
| US6504030
(Pediatric)
| Polymorphic form of clopidogrel hydrogen sulphate |
10 Dec, 2019
(6 years ago)
| Expired |
| US6429210 | Polymorphic clopidogrel hydrogenesulphate form |
10 Jun, 2019
(6 years ago)
| Expired |
| US6504030 | Polymorphic form of clopidogrel hydrogen sulphate |
10 Jun, 2019
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Plavix's drug page
18. Renvela
Renvela is protected by 7 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7985418 | Aliphatic amine polymer salts for tableting |
27 Oct, 2025
(2 months ago)
| Expired |
| US5667775 | Phosphate-binding polymers for oral administration |
16 Sep, 2014
(11 years ago)
| Expired |
| US5496545 | Phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US6509013 | Method of making phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US6858203 | Method of making phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US7014846 | Phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
| US7459151 | Phosphate-binding polymers for oral administration |
11 Aug, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Renvela's drug page
19. Soliqua 100/33
Soliqua 100/33 is protected by 26 patents, out of which 18 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9950039 | Insulin glargine/lixisenatide fixed ratio formulation |
10 Dec, 2035
(9 years from now)
| Active |
| US9717852 | Cartridge holder and pen-type injector |
08 Apr, 2033
(7 years from now)
| Active |
| US9821032 | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
09 May, 2032
(6 years from now)
| Active |
| US10029011 | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
11 Nov, 2030
(4 years from now)
| Active |
| US9707176 | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
11 Nov, 2030
(4 years from now)
| Active |
| US10117909 | Combination of an insulin and a GLP-1 agonist |
09 Oct, 2029
(3 years from now)
| Active |
| US9526764 | Combination of an insulin and a GLP-1-agonist |
09 Oct, 2029
(3 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(1 year, 7 months from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(9 months ago)
| Expired |
| US8512297 | Pen-type injector |
15 Sep, 2024
(1 year, 4 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(1 year, 4 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(1 year, 7 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(1 year, 9 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| USRE45313 | Exendin variant peptides |
12 Jul, 2020
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Soliqua 100/33's drug page
20. Taxotere
Taxotere is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5438072
(Pediatric)
| Taxoid-based compositions |
22 May, 2014
(11 years ago)
| Expired |
| US5438072 | Taxoid-based compositions |
22 Nov, 2013
(12 years ago)
| Expired |
| US5698582
(Pediatric)
| Compositions containing taxane derivatives |
03 Jan, 2013
(13 years ago)
| Expired |
| US5714512
(Pediatric)
| Compositions containing taxane derivatives |
03 Jan, 2013
(13 years ago)
| Expired |
| US5750561
(Pediatric)
| Compositions containing taxane derivatives |
03 Jan, 2013
(13 years ago)
| Expired |
| US5698582 | Compositions containing taxane derivatives |
03 Jul, 2012
(13 years ago)
| Expired |
| US5714512 | Compositions containing taxane derivatives |
03 Jul, 2012
(13 years ago)
| Expired |
| US5750561 | Compositions containing taxane derivatives |
03 Jul, 2012
(13 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Taxotere's drug page
21. Toujeo Max Solostar
Toujeo Max Solostar is protected by 20 patents, out of which 17 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10369291 | Mechanism for a drug delivery device |
16 Sep, 2035
(9 years from now)
| Active |
| US9345750 | Long-acting formulations of insulin |
18 May, 2031
(5 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(1 year, 7 months from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(9 months ago)
| Expired |
| US8512297 | Pen-type injector |
15 Sep, 2024
(1 year, 4 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(1 year, 4 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(1 year, 7 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(1 year, 9 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Toujeo Max Solostar's drug page
22. Toujeo Solostar
Toujeo Solostar is protected by 21 patents, out of which 17 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10369291 | Mechanism for a drug delivery device |
16 Sep, 2035
(9 years from now)
| Active |
| US9345750 | Long-acting formulations of insulin |
18 May, 2031
(5 years from now)
| Active |
| US7918833
(Pediatric)
| Pen-type injector |
23 Mar, 2028
(2 years from now)
| Active |
| US7918833 | Pen-type injector |
23 Sep, 2027
(1 year, 7 months from now)
| Active |
| US8679069 | Pen-type injector |
12 Apr, 2025
(9 months ago)
| Expired |
| US8512297 | Pen-type injector |
15 Sep, 2024
(1 year, 4 months ago)
| Expired |
| US9561331 | Drive mechanisms suitable for use in drug delivery devices |
28 Aug, 2024
(1 year, 4 months ago)
| Expired |
| US9623189 | Relating to drive mechanisms suitable for use in drug delivery devices |
19 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9533105 | Drive mechanisms suitable for use in drug delivery devices |
17 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US9604009 | Drive mechanisms suitable for use in drug delivery devices |
16 Aug, 2024
(1 year, 5 months ago)
| Expired |
| US8992486 | Pen-type injector |
05 Jun, 2024
(1 year, 7 months ago)
| Expired |
| US9011391 | Pen-type injector |
26 Mar, 2024
(1 year, 9 months ago)
| Expired |
| US8556864 | Drive mechanisms suitable for use in drug delivery devices |
03 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US8603044 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9233211 | Relating to a pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9408979 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9526844 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9604008 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9610409 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9775954 | Pen-type injector |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
| US9827379 | Drive mechanisms suitable for use in drug delivery devices |
02 Mar, 2024
(1 year, 10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Toujeo Solostar's drug page